Background: Most preterm infants born at 29-32 weeks gestation now avoid intubation in early life, and thus lack the usual conduit through which exogenous surfactant is given if needed. Objective: The aim of this work was to examine whether a technique of minimally invasive surfactant therapy used selectively at 29-32 weeks gestation would improve outcomes. Methods: We studied the impact of selective administration of surfactant (poractant alfa 100-200 mg/kg) by thin catheter in infants with respiratory distress syndrome on continuous positive airway pressure (CPAP). The threshold for consideration of treatment was CPAP ≥7 cm H2O and FiO2 ≥0.35 prior to 24 h of life. In-hospital outcomes were compared before and after introducing minimally invasive surfactant therapy (epochs 1 and 2, respectively). Results: During epoch 2, of 266 infants commencing CPAP, 51 (19%) reached the treatment threshold. Thirty-seven infants received surfactant via thin catheter, and CPAP failure was avoided in 34 of these (92%). For the overall cohort of infants at 29-32 weeks gestation, after the introduction of minimally invasive surfactant therapy, there were reductions in CPAP failure (epoch 1: 14%, epoch 2: 7.2%) and average days of intubation, with equivalent surfactant use and days of respiratory support (intubation + CPAP). Pneumothorax was substantially reduced (from 8.0 to 2.4%). These findings were mirrored within the subgroups reaching the severity threshold in each epoch. The incidence of bronchopulmonary dysplasia was low in both epochs. Conclusions: Selective use of minimally invasive surfactant therapy at 29-32 weeks gestation permits a primary CPAP strategy to be pursued with a high rate of success, and a low risk of pneumothorax.

1.
Jobe AH: Transition/adaptation in the delivery room and less RDS: “Don't just do something, stand there!” J Pediatr 2005;147:284-286.
2.
Blennow M, Bohlin K: Surfactant and noninvasive ventilation. Neonatology 2015;107:330-336.
3.
Chow SSW, Le Marsney R, Hossain S, Haslam R, Lui K: Report of the Australian and New Zealand Neonatal Network 2013. Sydney, ANZNN, 2015.
4.
Abdel-Latif ME, Osborn DA: Pharyngeal instillation of surfactant before the first breath for prevention of morbidity and mortality in preterm infants at risk of respiratory distress syndrome. Cochrane Database Syst Rev 2011;3:CD008311.
5.
Ammari A, Suri M, Milisavljevic V, Sahni R, Bateman D, Sanocka U, Ruzal-Shapiro C, Wung JT, Polin RA: Variables associated with the early failure of nasal CPAP in very low birth weight infants. J Pediatr 2005;147:341-347.
6.
Dargaville PA, Aiyappan A, De Paoli AG, Dalton RG, Kuschel CA, Kamlin CO, Orsini F, Carlin JB, Davis PG: Continuous positive airway pressure failure in preterm infants: incidence, predictors and consequences. Neonatology 2013;104:8-14.
7.
Dargaville PA, Gerber A, Johansson S, De Paoli AG, Kamlin CO, Orsini F, Davis PG: Incidence and outcome of CPAP failure in preterm infants. Pediatrics 2016;138:e20153985.
8.
Kribs A, Hartel C, Kattner E, Vochem M, Kuster H, Moller J, Muller D, Segerer H, Wieg C, Gebauer C, Nikischin W, Wense A, Herting E, Roth B, Gopel W: Surfactant without intubation in preterm infants with respiratory distress: first multi-center data. Klin Padiatr 2010;222:13-17.
9.
Kanmaz HG, Erdeve O, Canpolat FE, Mutlu B, Dilmen U: Surfactant administration via thin catheter during spontaneous breathing: randomized controlled trial. Pediatrics 2013;131:e502-e509.
10.
Dargaville PA, Aiyappan A, De Paoli AG, Kuschel CA, Kamlin CO, Carlin JB, Davis PG: Minimally-invasive surfactant therapy in preterm infants on continuous positive airway pressure. Arch Dis Child Fetal Neonatal Ed 2013;98:F122-F126.
11.
Kribs A, Roll C, Gopel W, Wieg C, Groneck P, Laux R, Teig N, Hoehn T, Bohm W, Welzing L, Vochem M, Hoppenz M, Buhrer C, Mehler K, Stutzer H, Franklin J, Stohr A, Herting E, Roth B: Nonintubated surfactant application vs conventional therapy in extremely preterm infants: a randomized clinical trial. JAMA Pediatr 2015;169:723-730.
12.
Mohammadizadeh M, Ardestani AG, Sadeghnia AR: Early administration of surfactant via a thin intratracheal catheter in preterm infants with respiratory distress syndrome: feasibility and outcome. J Res Pharm Pract 2015;4:31-36.
13.
Bao Y, Zhang G, Wu M, Ma L, Zhu J: A pilot study of less invasive surfactant administration in very preterm infants in a Chinese tertiary center. BMC Pediatr 2015;15:21.
14.
Mirnia K, Heidarzadeh M, Hosseini M, Balila M, Ghojazadeh M: Comparison outcome of surfactant administration via tracheal catheterization during spontaneous breathing with INSURE. Med J Islamic World Acad Sci 2013;21:143-148.
15.
Göpel W, Kribs A, Ziegler A, Laux R, Hoehn T, Wieg C, Siegel J, Avenarius S, von der WA, Vochem M, Groneck P, Weller U, Moller J, Hartel C, Haller S, Roth B, Herting E: Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet 2011;378:1627-1634.
16.
Papile LA, Burstein J, Burstein R, Koffler H: Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978;92:529-534.
17.
Aly H, Massaro AN, Patel K, El Mohandes AA: Is it safer to intubate premature infants in the delivery room? Pediatrics 2005;115:1660-1665.
18.
More K, Sakhuja P, Shah PS: Minimally invasive surfactant administration in preterm infants: a meta-narrative review. JAMA Pediatr 2014;168:901-908.
19.
Rigo V, Lefebvre C, Broux I: Surfactant instillation in spontaneously breathing preterm infants: a systematic review and meta-analysis. Eur J Pediatr 2016;175:1933-1942.
20.
Ali E, Abdel WM, Alsalami Z, Abouseif H, Gottschalk T, Rabbani R, Zarychanski R, Abou-Setta AM: New modalities to deliver surfactant in premature infants: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 2016;29:3519-3524.
21.
Isayama T, Iwami H, McDonald S, Beyene J: Association of noninvasive ventilation strategies with mortality and bronchopulmonary dysplasia among preterm infants: a systematic review and meta-analysis. JAMA 2016;316:611-624.
22.
Aldana-Aguirre JC, Pinto M, Featherstone RM, Kumar M: Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2017;102:F17-F23.
23.
Klotz D, Porcaro U, Fleck T, Fuchs H: European perspective on less invasive surfactant administration - a survey. Eur J Pediatr 2017;176:147-154.
24.
Aguar M, Cernada M, Brugada M, Gimeno A, Gutierrez A, Vento M: Minimally invasive surfactant therapy with a gastric tube is as effective as the intubation, surfactant, and extubation technique in preterm babies. Acta Paediatr 2014;103:e229-e233.
25.
Klebermass-Schrehof K, Wald M, Schwindt J, Grill A, Prusa AR, Haiden N, Hayde M, Waldhoer T, Fuiko R, Berger A: Less invasive surfactant administration in extremely preterm infants: impact on mortality and morbidity. Neonatology 2013;103:252-258.
26.
Göpel W, Kribs A, Hartel C, Avenarius S, Teig N, Groneck P, Olbertz D, Roll C, Vochem M, Weller U, von der Wense A, Wieg C, Wintgens J, Preuss M, Ziegler A, Roth B, Herting E: Less invasive surfactant administration is associated with improved pulmonary outcomes in spontaneously breathing preterm infants. Acta Paediatr 2015;104:241-246.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.